Skip to main navigation

Press Releases

Year

Nov 27, 2023

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)

Nov 15, 2023

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

Nov 06, 2023

Autolus Therapeutics announces participation in upcoming conferences

Nov 02, 2023

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations

Nov 02, 2023

Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Oct 17, 2023

Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus

Oct 11, 2023

Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

Oct 11, 2023

Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

Sep 05, 2023

Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood

Aug 03, 2023

Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Displaying 1 - 10 of 34